News | December 12, 2024
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Sustainability is integral to Biocon's business purpose
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Yesafili, received marketing authorization approval from the European Commission for the European Union
Subscribe To Our Newsletter & Stay Updated
